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ABSTRACT. 16 
Fungi establish a complex network of biological interactions with other organisms in 17 
nature. In many cases, these involve the production of toxins for survival or colonization 18 
purposes. Among these toxins, ribotoxins stand out as promising candidates for their use in 19 
biotechnological applications. They constitute a group of highly specific extracellular 20 
ribonucleases that target a universally conserved sequence of RNA in the ribosome, the 21 
sarcin-ricin loop. The detailed molecular study of this family of toxic proteins over the past 22 
decades has highlighted their potential in applied research. Remarkable examples would be 23 
the recent studies in the field of cancer research with promising results involving ribotoxin-24 
based immunotoxins. On the other hand, some ribotoxin-producer fungi have already been 25 
studied in the control of insect pests. The recent role of ribotoxins as insecticides could 26 
allow their employment in formulas and even as baculovirus-based biopesticides. 27 
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Moreover, considering the important role of their target in the ribosome, they can be used 28 
as tools to study how ribosome biogenesis is regulated and, eventually, may contribute to a 29 
better understanding of some ribosomopathies. 30 
 31 
KEYWORDS: fungal ribotoxins, ribonuclease (RNase), ribosome, sarcin-ricin loop 32 
(SRL), insecticide, biopesticide, immunotoxin, cancer, ribosomopathies. 33 
 34 
1. INTRODUCTION. 35 
Organisms populate almost any ecological niche of the planet and establish a high variety 36 
of biological interactions, ranging from mutualism to antagonism, mainly in search for 37 
resources to survive (light, nutrients, water, etc.). In particular, fungi constitute a rich 38 
source of nitrogen and phosphorous for arthropods and are under constant attack by 39 
fungivores such as collembolan, mites and insects
 
[1]. However, they can also present 40 
mutualistic relationships like those established with fungus farming ants. Thus, a complex 41 
network of interactions is established in nature involving predatory, defensive and 42 
mutualistic relationships. In this context, fungi produce a great variety of toxins, many of 43 
them are proteins. These toxins are secreted with many different purposes, although self-44 
defense and fungi development have been suggested to be their principal functions. 45 
Fungal ribotoxins are a family of extracellular ribonucleases that have been studied in detail 46 
since their discovery in the early 1960’s. They are not the only extracellular ribonucleases 47 
(RNases) produced by filamentous fungi, but are the only ones shown to display cytotoxic 48 
activity (Fig. 1A). Ribotoxins are produced by several fungi species, mostly from the genus 49 
Aspergillus, although other entomopathogenic fungi such as Hirsutella thompsonii or 50 
Metarhizium anisopliae also produce them [2-6]. They are highly specific, exerting their 51 
ribonucleolytic activity on the larger RNA molecule (rRNA) of the ribosome. From this 52 
perspective, they could be included in the group of ribosome-inactivating proteins (RIPs), 53 
however, this term usually refers to those toxins with N-glycosidase activity and plant 54 
origin, best represented by ricin, a toxin found in the seeds of the castor bean plant Ricinus 55 
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communis. Both RIPs and ribotoxins target the same universally conserved sequence of 56 
rRNA, the so-called sarcin-ricin loop (SRL), by either depurinating a single nucleotide or 57 
cleaving a unique phosphodiester bond, respectively (Fig. 1B). However, the mechanisms 58 
employed by both types of toxins to reach their target are quite different [7-8]. 59 
Even though the biological function of ribotoxins has not been cleared up yet, several 60 
studies have shown the insecticidal properties of at least two of these proteins, supporting 61 
their involvement in defense and parasitism [9-11]. The detailed study of the structure and 62 
function of this family of toxic proteins has highlighted their potential use in 63 
biotechnological applications, either as bioinsecticides to control insect pests [12] or as 64 
antitumor agents in human therapies [13-14]. Moreover, they could also be used as specific 65 
tools for the study of human ribosome-related diseases, the so-called ribosomopathies [15-66 
16]. 67 
2. FUNGAL RIBOTOXINS. 68 
Ribotoxins are not the only RNases produced by fungi. Indeed, they are part of a much 69 
wider group of fungal extracellular RNases. Ribotoxins are larger than non-toxic fungal 70 
RNases but still small proteins of about 150 amino acids, and generally basic. The main 71 
structural difference between non-toxic RNases, such as RNases T1 or U2, and ribotoxins 72 
would be that the latter contain longer and positively charged loops, which have been 73 
suggested to be the structural basis of their toxicity [17]. Identification of these structural 74 
features that make ribotoxins such efficient natural killers would be a major step towards 75 
their utilization as specifically targeted weapons against insect pests or different human 76 
pathologies. So far, the best characterized ribotoxins are α-sarcin, restrictocin, Aspf1, and 77 
hirsutellin A (HtA). The first three, produced by different Aspergillus spp., show a high 78 
degree of conservation with sequence identities above 85%. However, HtA, a ribotoxin 79 
produced by the entomopathogenic fungus Hirsutella thompsonii, only shares 25% of 80 
sequence identity with them (Fig. 1). This observation confirmed that ribotoxins spread 81 
across fungal species, and are not only restricted to the genus Aspergillus [2-3, 18-19]. 82 
Figure 1: Ribotoxins structure and sequence features. 83 
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A) The three dimensional structures of the three most representative ribotoxins and RNase 84 
T1 are shown (PDB IDs: 1DE3, 1AQZ, 2KAA, 9RNT). In -sarcin elements of secondary 85 
structure are shown. Diagrams were generated with PyMOL [20]. B) Sequence alignment 86 
of the most representative fungal RNases from the RNase T1 family. Conserved Cys 87 
forming disulphide bridges (C) as well as the active site residues (*) are indicated. 88 
Conserved amino acids (light grey boxes) in at least seven sequences are highlighted in 89 
black. Elements of secondary structure are displayed by the same colors as in A. 90 
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 92 
The ribonucleolytic activity of ribotoxins is extremely specific, targeting a sequence of 93 
rRNA, the SRL, highly conserved in all ribosomes (Fig. 2). This sequence is located on the 94 
larger molecule of rRNA of the large ribosomal subunit. During translation, the SRL 95 
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together with the uL11-binding region, the L7/L12 stalk (P1/P2 in yeast) and ribosomal 96 
proteins uL6 and uL14, constitute the elongation factor-binding site that is required for 97 
correct functioning of the ribosome [21-22]. The SRL structure consists of a distorted 98 
hairpin, and the most significant structural features are a GAGA tetraloop and a bulged G 99 
motif. Ribotoxins cleave a single phosphodiester bond of the GAGA tetraloop, producing a 100 
small fragment of 300-400 nucleotides of rRNA (depending on the ribosome origin), 101 
known as the α-fragment. They are cyclizing RNases displaying the general acid-base type 102 
endonucleolytic cleavage of RNA mechanism in two steps, just like other members of the 103 
RNase T1 family [4, 23]. Cleavage of this phosphodiester bond inhibits protein 104 
biosynthesis and produces cell death by apoptosis [24]. 105 
Figure 2.- The target of ribotoxins: the ribosome. 106 
A) Three-dimensional structure of the large ribosomal subunit of Escherichia coli (PDB ID: 107 
2AW4). The location of L1 and L7/L12 stalks (absent in this crystal) and E, P and A sites 108 
are indicated. Conserved proteins around the SRL (orange) appear in different colors: uL6 109 
(green), uL11 (red), uL14 (blue). Other ribosomal proteins appear in light gray. 23S (dark 110 
gray) and 5S (cyan) rRNAs are also shown. B) SRL structure. The bulged G (red), the 111 
GAGA tetraloop (blue), the bond cleaved by α-sarcin and the adenine depurinated by ricin, 112 
are indicated. 113 
 114 
The three-dimensional structure of several ribotoxins is known at atomic resolution (Fig. 115 
1A) [25-27], and mutational analyses have allowed the assignment of specific roles to 116 
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different residues (implication in the catalysis, ribosome and SRL recognition, interaction 117 
with the cell membrane, etc.). In the case of α-sarcin, the catalytic residues are His 50, Glu 118 
96 and His 137 (Fig. 1B). These three residues are required for the specific inactivation of 119 
ribosomes. Additional mutational studies showed that Tyr 48, Arg 121 and Leu 145, 120 
although not essential, would also contribute to the ribotoxin activity of α-sarcin [28-30] 121 
(Fig. 1B). The equivalent residues in HtA (His 42, Glu 66 and His 113) were identified by 122 
structural comparison, showing that the catalytic residues are conserved, but also presenting 123 
other features closer to the T1-like RNases (Phe 126 instead of the equivalent Leu 145, for 124 
example) or even some others which were completely new (Asp 40 instead of Tyr 48) [31] 125 
(Fig. 1B). Mutagenesis studies have indeed revealed that the active site of HtA would 126 
provide a more adaptable microenvironment than the one described for α-sarcin being able 127 
to better accommodate electrostatic and structural changes [31-33]. 128 
The toxicity of ribotoxins results from the combination of their highly specific RNase 129 
activity and their ability to cross membranes. So far, no protein receptor for ribotoxins has 130 
been found in the cell. For that reason, even though ribotoxins can potentially inactivate 131 
any ribosome, the lipid composition of cell membrane plays an important role in their 132 
cytotoxic specific activity. Accordingly, it has been described how ribotoxins are more 133 
efficient on transformed or virus-infected cells, most likely due to altered permeability 134 
and/or composition of their cell membrane [24, 34]. In insects, lipidic membrane is thinner 135 
and more hydrophilic than in other eukaryotes, therefore, more accessible and sensitive to 136 
ribotoxins [11, 35]. The use of lipid model systems has proven that α-sarcin interacts with 137 
lipid vesicles enriched in acidic phospholipids. This interaction causes vesicle aggregation 138 
followed by fusion and intermixing of phospholipids and, finally, leakage of their aqueous 139 
contents [36-37]. However, this mechanism does not seem to be conserved among 140 
ribotoxins. HtA does not promote vesicle aggregation even though it shows a higher 141 
membrane-permeabilizing ability than α-sarcin in leakage experiments [5, 11]. In α-sarcin, 142 
the region comprising residues 116-139 was thought to participate in the hydrophobic 143 
interaction with membranes [38-39] and recently it was proposed that Lys residues 111 and 144 
114, in loop 3, would also take part in the electrostatic interactions needed to bring vesicles 145 
into contact [40]. For HtA, a role in membrane-permeabilizing activity has been proposed 146 
for Trp71 and Trp78 [32]. The ability to interact with lipid membranes has also been 147 
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associated with the N-terminal β-hairpin of ribotoxins. Deletion of this positively charged 148 
region in α-sarcin produces a non-toxic but active ribonuclease with altered membrane 149 
interaction properties [41]. It is in this region where HtA and restrictocin show more 150 
variability when compared to α-sarcin. The N-terminal β-hairpin of HtA is much shorter 151 
(Fig. 1), but this truncation appears to be compensated by the extension of loop 5, which 152 
also exhibits a higher amount of positive charges [32-33]. 153 
The positively charged surface of ribotoxins allows them to establish favorable electrostatic 154 
interactions with the ribosome [42-44]. Moreover, the high specificity of ribotoxins 155 
requires of additional elements besides the active site capable of interacting with the 156 
ribosome to recognize the SRL. So far, several regions have been proposed to participate in 157 
the specific recognition of the SRL and other ribosomal elements. The Lys-rich region of 158 
loop 3 may interact with a phosphodiester bond around the bulged G of the SRL, whereas 159 
residues 51-55 of loop 2 and some residues of loop 5 may contact the GAGA tetraloop that 160 
is cleaved by the toxin [42, 45]
 
(Fig. 1 and 2). Docking models using the Haloarcula 161 
marismortui ribosome and α-sarcin structures suggested that apart from interactions with 162 
the SRL, α-sarcin could interact with neighboring ribosomal proteins. A short sequence of 163 
loop 2 would contact ribosomal protein uL6 and the N-terminal β-hairpin, specifically the 164 
stretch 11-16, would interact with ribosomal protein uL14 (Fig. 1 and 2). In addition, other 165 
ribosomal regions involved in the recruiting of elongation factors during translation could 166 
also establish interactions with toxins. That is the case of the ribosomal stalk proteins and 167 
RIPs like ricin, trichosantin and Shiga-like toxins [46]. The ribosomal stalk is a protruding 168 
structure of the ribosome that serves as an anchoring platform for elongation factors and by 169 
several RIPs to further recognize the SRL. Despite sharing the same target, not all RIPs 170 
behave identically, since no interaction has been found between pokeweed antiviral protein 171 
and the eukaryotic stalk proteins [47]. In the case of ribotoxins, the eukaryotic ribosomal 172 
stalk does not participate in α-sarcin inactivation of the ribosome [8]. This result suggests 173 
that ribotoxins use a different mechanism of ribosome recognition than that used by plant 174 
RIPs like ricin. 175 
Finally, besides the toxicity exerted by ribotoxins due to their catalytically inactivation of 176 
the ribosome, there are some studies highlighting the ability of -sarcin to inhibit protein 177 
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biosynthesis and promote cytotoxicity independently of its ribonucleolytic activity [48-49]. 178 
These observations suggest an alternative mechanism for cell death that still needs to be 179 
explored. 180 
3. THE GENUS ASPERGILLUS AND OTHER RIBOTOXIN-PRODUCER FUNGI. 181 
Fungal ribotoxins were first discovered in the 1960’s during a screening program searching 182 
for antibiotics and antitumor agents. The mold Aspergillus giganteus was found to produce 183 
a protein that could inhibit sarcoma and carcinoma induced in mice [50] which was named 184 
α-sarcin. Soon after, two other antitumor proteins with similar activity, restrictocin and 185 
mitogillin, were discovered in Aspergillus restrictus. More recent studies proved that all 186 
species assigned to Aspergillus section Clavati contain ribotoxin genes [18]. Aspergilli are 187 
a ubiquitous and complex group of filamentous fungi containing more than 185 species 188 
including human pathogens, like Aspergillus fumigatus, as well as others used in industry 189 
for the production of food and enzymes, like Aspergillus oryzae [51]. By 2008, the genome 190 
of seven species of Aspergillus had been sequenced. This was a promising step towards the 191 
understanding of fungi biology and evolution. Indeed, sequencing the genome of other 192 
fungi could also be used for the identification of new species that produce ribotoxins. 193 
Moreover, the comparison of these genomes with those from non-producer species could 194 
shed new light on the biological function of these proteins. 195 
Most filamentous fungi have a complex life cycle. Like other Ascomycota, some 196 
Aspergillus spp. can have both sexual and asexual reproductive cycles (Fig. 3). A. nidulans 197 
constitutes a good example to describe them since it can present both types of reproduction 198 
[52]. In the sexual reproduction, karyogamy (nuclei fusion) and meiosis take place. The 199 
fungus develops a fruiting body, the cleistothecium, which produces sexual spores or 200 
ascospores. During the asexual cycle, the mycelium, which develops from a single haploid 201 
spore, differentiates into many identical spores named conidia or conidiospores, which can 202 
form a new web of hyphae. There are only a few studies of ribotoxin expression by their 203 
natural host and its role in its life cycle. In those, the presence of ribotoxins has been 204 
detected during the asexual reproduction of A. restrictus. The ribotoxin restrictocin, which 205 
is almost indistinguishable from α-sarcin, is produced by A. restrictus at a very specific 206 
moment of fungal development, the initial steps of conidiophore formation, and it is 207 
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degraded afterwards [53-54]. Furthermore, in solid medium restrictocin remained attached 208 
exclusively to the phialides and disappeared after conidia maturation (Fig. 3). Plausible 209 
explanations for this pattern in the ribotoxin expression could be that restrictocin has a role 210 
in the process of conidiation, or a protective function of the maturing conidia from 211 
predators until the development is complete. Once conidiation is finished, restrictocin 212 
would be degraded so that fungus-feeding insects could externally or internally carry spores 213 
to new locations for spreading the fungus. Following the idea of a protective function of 214 
ribotoxins during maturation of conidia, there are some studies on the different feeding 215 
behavior of the fungivorous beetle Carpophilus freemani upon restrictocin production [9]. 216 
Feeding of C. freemani adults on A. restrictus decreased during conidia formation, 217 
something that was not observed when they fed on A. nidulans at the same developmental 218 
stage. This deterrence of insect feeding could be related to an increase in restrictocin 219 
production by A. restrictus and not by A. nidulans. Heterologous expression of restrictocin 220 
in A. nidulans also inhibited insect feeding by C. freemani beetles [10]. 221 
 222 
Figure 3.- Life cycle of Aspergillus and suggested localization of ribotoxins. 223 
Aspergillus can enter a sexual or an asexual reproductive cycle. During the sexual cycle, the 224 
mycelium forms a fruiting body, the cleistothecium, which holds the ascospores that once 225 
released into the environment can form a new mycelium. In the asexual reproduction, the 226 
mycelium differentiates into identical asexual spores or conidiospores. Ribotoxins would be 227 
produced during maturation of the conidia, and would be located on the edge of the 228 
phialides (shown in red). Additionally, a parasexual cycle can take place in Aspergillus (not 229 
shown). 230 
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 232 
As mentioned before, the production of ribotoxins is not restricted to Aspergillus [2-3, 6, 233 
18-19, 55]. The genus Hirsutella includes over 50 fungal species that infect many species 234 
of invertebrates. The entomopathogenic fungus H. thompsonii also produces a ribotoxin. 235 
This fungus is known to cause natural epizootics in populations of eriophyid mites. Under 236 
in vivo conditions, the conidia of H. thompsonii attach to the cuticle of the host, germinate 237 
and penetrate through it. The hyphae then grow inside the insect and reproduce asexually, 238 
contacting new hosts to begin a new cycle of infection [56]. Studies of the toxicity and 239 
pathology of crude filtrates of this fungus during the 1990’s revealed a high specificity for 240 
the subclass Acari, although it was also toxic for other arthropods like moth, flies and 241 
mosquito larvae [57]. The role of toxins in the pathogenesis of insect infection by H. 242 
thompsonii has been investigated as well. It was known that other entomopathogenic fungi 243 
like M. anisopliae and Beauveria bassiana produce cyclic peptides that are toxic to insect 244 
[58]. These peptides induced immediate paralysis and quick mortality when injected into 245 
Galleria mellonella larvae. Symptoms upon injection of H. thompsonii culture filtrates 246 
were different and rather slower, but still lethal for G. mellonella larvae. Several 247 
investigations led to the identification of hirsutellin A, a protein produced by H. thompsonii 248 
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var thompsonii with insecticidal activity against G. mellonella and Aedes aegypti larvae 249 
[19, 59]. Analysis of 162 strains of H. thompsonii revealed the presence of the HtA gene in 250 
100 strains but the expression of HtA was poorly correlated with the mortality rates induced 251 
by broth filtrates in G. mellonella, suggesting that there could be additional toxic factors 252 
involved in the insecticidal activity of the fungus [60]. There are no studies on the exact 253 
localization of HtA in the fungus, like those performed with A. restrictus. Therefore the 254 
production of this toxin cannot be linked to a developmental stage yet. Soon after its 255 
discovery, HtA was related to ribotoxins due to its ability to specifically cleave rRNA on 256 
Spodoptera frugiperda cells (Sf9), inhibiting cell growth [19, 55]. HtA was then subjected 257 
to a fine structural and functional characterization, demonstrating that despite its smaller 258 
size and low sequence identity, it was a ribotoxin [5, 31-33, 61]. 259 
In fact, characterization of HtA opened up the possibility of an insecticidal function of 260 
ribotoxins in general. This idea is also supported by the fact that Aspergillus, the main 261 
ribotoxin producer known so far, shares feeding niche with several insects and, as a way to 262 
compete for survival, it could have developed weapons like ribotoxins. Purified restrictocin 263 
included in the insects’ diet killed C. freemani and S. frugiperda larvae, and deterred 264 
feeding of adult C. freemani [9]. A detailed comparison of the activity of HtA and α-sarcin 265 
proved that the latter is nearly as toxic as HtA against insect larvae, insect cell cultures and 266 
insect ribosomes [11]. Biochemical characterization of the activity of ribotoxins against 267 
insect cells showed how HtA and α-sarcin cause protein synthesis inhibition and the release 268 
of the characteristic α-fragment resulting from the rRNA cleavage [11], just as it had been 269 
previously shown with ribosomes of different origin [4-5, 21]. In the conditions assayed, 270 
HtA is significantly more active than α-sarcin against isolated insect ribosomes, suggesting 271 
that the passage across the cell membrane might be the rate-limiting step for their cytotoxic 272 
activity. Of course, in a natural environment additional factors may influence their 273 
efficiency, such as their natural biosynthesis and extracellular export, stability in a 274 
particular environment or accessibility to their target. Reinforcing this hypothesis about 275 
their insecticidal natural function, a new ribotoxin, very similar to HtA, has been recently 276 
cloned and characterized [6]. This small ribotoxin is produced by the fungus M. anisopliae 277 
and therefore has been named as anisoplin. 278 
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The fact that ribotoxins can inactivate every ribosome known raises the question of how 279 
fungi protect their own ribosomes [62]. Ribotoxins are synthesized as precursors that are 280 
processed inside cellular membrane compartments. Protection of the producing cells must 281 
rely on a very efficient recognition of the signal sequences and an adequate 282 
compartmentalization before they are secreted to the extracellular medium [4, 63-65]. In 283 
fact, when the leader sequence was altered or changed by a different one, heterologous 284 
expression of restrictocin in A. nidulans showed reduced transcript levels and enhanced 285 
cellular lysis, and the ribotoxin was not always localized in the conidiophores of the fungus 286 
[66], suggesting that the native leader sequence of restrictocin is highly efficient in its role 287 
of protecting fungi during secretion. The restrictocin gene in A. restrictus has an intron at 288 
the beginning of its sequence [67]. Recently, a study has proven that introns can be used to 289 
attenuate toxicity of barnase for its use in suicide gene therapy [68], so perhaps the 290 
existence of an intron in restrictocin is an additional example of the strategies used by these 291 
fungi to attenuate ribotoxins’ toxicity against their own ribosomes during their synthesis 292 
and secretion to the extracellular medium. 293 
4. THE POTENTIAL BIOTECHNOLOGICAL USES OF FUNGAL RIBOTOXINS.  294 
4.1. IMMUNOTOXINS.  295 
Even though the role of ribotoxins in nature is not well determined yet, they already have 296 
been tested for their use as therapeutic agents. In fact, they were first discovered as 297 
antitumor agents, although further studies revealed an unspecific cytotoxicity against non-298 
tumor cells [69]. Later on, the interest for ribotoxins revived, since they could be used as 299 
part of immunotoxins in antitumor therapies. Immunotoxins are usually chimeric molecules 300 
composed of a specific antibody fragment, responsible for targeting a specific cell surface 301 
antigen, linked to a toxin moiety that promotes cell death (Fig. 4A) [70-71]. To overcome 302 
the great size of the full-length antibody, something that could hinder its penetration 303 
through solid tumors, new strategies have been developed where only the antibody variable 304 
domains are used. Regarding the toxic moiety, several toxins have been used such as ricin, 305 
Pseudomonas exotoxin A and diphtheria toxin [72]. Despite being highly effective, in 306 
many cases they showed undesirable side effects. 307 
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Fungal ribotoxins show features that make them appropriate candidates for the construction 308 
of immunotoxins: their small size, high thermostability, poor immunogenicity, resistance to 309 
proteases and, most importantly, their high efficiency in inactivating ribosomes. 310 
Accordingly, several colon cancer-specific immunotoxins containing ribotoxins (α-sarcin) 311 
or other fungal RNases (RNase T1) as the toxic component have been designed and 312 
characterized [73-74]. HtA has also been used to create an immunotoxin, using an 313 
engineered variant that is unable to cross membranes but still retains the ribonucleolytic 314 
activity [13]. This variant seems to be innocuous for cells that do not contain the 315 
specifically targeted antigen. Therefore, it might be safer, with reduced unwanted side 316 
effects during cancer therapy. 317 
Figure 4.- Ribotoxins as immunotherapeutic agents. 318 
(A) General structure of an immunotoxin, composed of a specific antibody fragment 319 
responsible for targeting to a specific cell type linked to a toxin moiety, ribotoxins or non-320 
toxic ribonucleases like RNase T1, which promote cell death. (B) IMTXA33αs, an 321 
immunotoxin that contains α-sarcin as the toxic domain, has been tested in nude mice. 322 
 323 
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The toxicity of an immunotoxin depends on many molecular aspects, such as the antigen 324 
binding affinity, internalization rate, intracellular processing, toxin release and intrinsic 325 
toxicity. Accordingly, the intracellular trafficking of ribotoxin-based immunotoxins has 326 
been studied, showing how they are internalized via early endosomes, following different 327 
pathways depending on the toxin used until they reach the cytosol [13, 75]. Finally, a step 328 
further in the therapeutic use of ribotoxin-based immunotoxins has been done showing the 329 
efficiency of the α-sarcin-based immunotoxin IMTXA33αs, which inhibits tumor growth as 330 
well as angiogenesis in nude mice harboring colon cancer xenografts [14] (Fig. 4B). This 331 
result can be considered the proof of concept that immunotoxins based on ribotoxins may 332 
be a unique therapeutic tool against different tumor pathologies. Moreover, an 333 
immunotoxin containing a deimmunized variant of α-sarcin showing a complete lack of T 334 
cell activation in in vitro assays have been recently described [76]. These results support 335 
the design of a new generation of therapeutic deimmunized ribotoxins-based 336 
immunotoxins. 337 
Apart from their potential antitumor effect, the therapeutic use of immunotoxins has been 338 
already described for other multifactorial disorders like HIV infection [77] or allergic 339 
reactions [78-79]. Few studies have been focused on directing toxin action to allergen-340 
reactive cells through the use of the high-affinity IgE receptor (FcεRI) as a target [80-81]. 341 
Despite of the significant decrease in IgE levels and mast cell degranulation, immunotoxin 342 
effects were accompanied by the onset of adverse side effects, presumably due to the high 343 
immunogenicity of plant and bacteria toxin-based immunoconjugates. Accordingly, new 344 
strategies for allergy treatment based on either non-specific or specific immunotherapies 345 
using immunotoxins arise as innovative and potentially effective approaches [82]. In this 346 
regard, the design of allergen-toxin conjugates [83-85] and α-sarcin-based chimeric 347 
molecules against specific immune cells involved in allergic symptoms (e.g. basophils, 348 
neutrophils, mast cells and the newly described innate type 2 lymphoid cells) are already 349 
ongoing [86-88]. 350 
4.2. ROLE IN ALLERGY AND ASPERGILLUS INFECTION. 351 
Not only ribotoxins can be used as therapeutic agents to alleviate allergy symptoms, but 352 
also Aspergillus spp. are human opportunistic pathogens that cause respiratory diseases like 353 
16 
 
asthma, ABPA (allergic bronchopulmonary aspergillosis), aspergilloma and severe 354 
infections, especially in immunocompromised people. A. fumigatus is the etiological agent 355 
in 80% of Aspergillus-related diseases. The ribotoxin Aspf1 is one of the main allergens of 356 
this fungus [89]. Although Aspf1 is not detected during the initial steps of infection, it 357 
seems to play a role in allergic-like pathogenic processes and some regions of the protein 358 
have been found to be significantly allergenic [90-91]. Diagnosis and immunotherapy 359 
against A. fumigatus allergy are frequently based on fungal extracts, but these are highly 360 
complex mixtures, with hundreds of different components very difficult to standardize, not 361 
to mention the high risk of anaphylactic side effects. Improvement of diagnosis and 362 
therapeutics has been focused on the recombinant production of allergens. Since the 363 
recombinant Aspf1 still maintains its cytotoxic activity, alternative non-cytotoxic ribotoxin 364 
molecules have been searched for, produced and characterized, showing that their N-365 
terminal β-hairpin is involved not only in cytotoxicity, but also in at least one allergenic 366 
epitope [91]. These non-cytotoxic and hypoallergenic mutant variants of Aspf1 and α-367 
sarcin might be suitable for their use in immunomodulating therapies against Aspergillus 368 
hypersensitivity and its diagnosis. Indeed, they have been produced in Lactococcus lactis, a 369 
GRAS (generally regarded as safe) microorganism that could be used in 370 
immunotherapeutic protocols for Aspf1-related diseases as a vaccination vehicle [92]. 371 
Furthermore, a mouse model of A. fumigatus sensitization has been established, that could 372 
be suitable for preclinical testing of recombinant allergens and their derivatives [93]. 373 
4.3. RIBOTOXINS AS PEST CONTROL AGENTS. 374 
The biological role of ribotoxins as insecticides could be used in the design and 375 
development of new biopesticides. The world population increases exponentially and it is 376 
estimated to reach 9.5 billion people by 2050. This rapid increase of population requires an 377 
equal increase in food resources. Every year, pest diseases are the cause of up to 40% losses 378 
in agriculture production around the world. For decades, pest control has relied on the use 379 
of chemical insecticides, such as the use of DDT (dichlorodiphenyltrichloroethane) in the 380 
1940s. They were in general highly potent, fast acting, cheap to produce and easy to 381 
deliver. Still, the poor species specificity, their toxicity and the emergence of pest resistance 382 
forced many countries to ban DDT and other chemical pesticides in the 1970s. Resistance 383 
17 
 
to pesticides has increased over the years due to the use of new chemical products. By 1992 384 
more than 500 species of mites and insects had developed resistance. Moreover, the cost of 385 
discovering, developing and registering new synthetic pesticides is so high that a new 386 
interest in alternative biological control methods has risen. Biopesticides have become an 387 
important component of environmentally friendly pest management. However, its use has 388 
not yet reached its potential, constituting only 2-3% of the insecticidal market [94]. The 389 
term biopesticides includes those pest control techniques that use microbial organisms 390 
(bacteria, fungi, viruses and nematodes) and/or their secondary metabolites like peptides 391 
and proteins. It even comprises genetically modified crops that improve their resistance to 392 
insect, fungal, viral or herbicide damage [95-96]. 393 
Entomopathogenic fungi have been used effectively as biological control agents to manage 394 
crop diseases, some of them being commercialized, like B. bassiana in the control of 395 
numerous insects and flies, or M. anisopliae against the mosquito Anopheles gambiae [97-396 
99]. Interestingly, and as mentioned above, this fungus produces an HtA-like ribotoxin, 397 
anisoplin [6]. H. thompsonii, the HtA producer, is also a well-known entomopathogenic 398 
fungus used in the biological control of the mite Varroa destructor, a honey bee 399 
ectoparasite [56, 97, 100]. This fungus has been shown to be even more effective than B. 400 
bassiana and M. anisopliae in some cases [101]. H. thompsonii was first registered in 1981 401 
as a mycoacaricide (Mycar) for the control of the citrus mite [102], but formulation 402 
problems, lack of field persistence and poor product stability in storage and transport 403 
resulted in the loss of this commercial product late in the 1980s. Attempts to overcome 404 
these obstacles have been made, evaluating the use of new formulations that improve the 405 
delivery, shelf life and field efficacy [103]. 406 
Genetic manipulation has also been used to increase virulence of the entomopathogenic 407 
fungi in pest control [104]. The first successful demonstration of an increased virulence was 408 
the overexpression of a protease capable of degrading the insect cuticle in the fungus M. 409 
anisopliae. Here the recombinant expression of ribotoxins could also play an important 410 
role. 411 
On the other hand, understanding the mechanism of infection of these fungi as well as the 412 
virulence factors involved might help in the design of new formulas for pest control. A 413 
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number of successful biopesticides are based on using compounds produced by the 414 
microbes rather than provoking the infection by the whole organism [94]. In this sense, the 415 
characterization of the activity of fungal ribotoxins against insects opens the possibility of 416 
using them as bioinsecticides, independently or in formulas where other compounds could 417 
be combined with the active agent [11-12]. The potential toxicity of ribotoxins against 418 
vertebrates could be overcome by the design of new variants such as the HtA Trp-residues 419 
mutants [13, 32]. These proteins retain the exquisite ribonucleolytic activity against the 420 
ribosome but are unable to enter mammalian cells and therefore are much less cytotoxic.  421 
Finally, insect pathogenic viruses like baculoviruses represent another strategy for 422 
biocontrol (Fig. 5). Natural baculoviruses have been used as effective biopesticides, 423 
although genetically engineered and recombinantly produced versions seem to be an even 424 
better alternative [105-106], as they can kill the host faster without conferring any 425 
ecological advantage over the wild-type species. Baculoviruses have the additional 426 
advantage of being an easy and stable formula with high specificity for the host. One 427 
example related to fungal pathogenesis is the design of an improved baculovirus that 428 
expresses a protease from A. fumigatus able to induce death in Spodoptera frugiperda 429 
larvae faster than the wild-type virus [107]. These results encourage the development of 430 
similar tools using ribotoxins. Baculovirus engineered to produce fungal ribotoxins, or 431 
improved variants of them, would be insect-selective, minimizing side toxic effects against 432 
other organisms. The only concern regarding the use of baculoviruses in pest control is the 433 
public opinion about the introduction of genetically modified viruses. However, new 434 
environmentally friendly versions are already being produced, which consist of viruses that 435 
become less active during serial passaging and spontaneously inactive after some time 436 
[108]. 437 
Figure 5.- Baculovirus-based biopesticides. 438 
Modified baculoviruses containing genes for insect-specific toxins, hormones or other 439 
enzymes are sprayed on the plant foliage and then ingested by the caterpillar or adult insect. 440 
Polyhedra solubilize in the insect's midgut due to an increase of pH, virions are released 441 
and start replicating within the nuclei of epithelial cells, producing more virions which are 442 
released in a budded form (early infection) or occluded in polyhedra (late infection). 443 
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 444 
 445 
4.4. THE STUDY OF RIBOSOME-RELATED DISEASES. RIBOSOME 446 
BIOGENESIS AS AN ADDITIONAL TARGET OF RIBOTOXINS. 447 
Ribosomes are among the finest molecular machines in the cell. They are essential for life, 448 
producing all the proteins required for cell growth. In humans, specific defects in their 449 
assembly lead to a heterogeneous number of diseases, named as ribosomopathies. These 450 
diseases have in common a ribosomal dysfunction, but differ significantly in mechanism, 451 
clinical symptoms and potential treatments (Table 1). Some disorders, such as Diamond-452 
Blackfan anemia (DBA), have been linked to mutations in ribosomal proteins, whereas 453 
others like the Schwachman-Diamond syndrome (SDS) or the Treacher Collins syndrome 454 
(TCS) are directly related to defective ribosome biogenesis [15-16, 109-110]. Clinical 455 
features of these ribosomopathies normally include bone marrow failure, developmental 456 
abnormalities and an elevated risk of cancer, although symptoms are diverse even among 457 
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patients with the same disease [15]. There are many unanswered questions regarding 458 
ribosomopathies. Among them, it is quite striking how, being that the ribosome is such a 459 
conserved machinery, mutations in ribosomal proteins can lead to such diversity of 460 
phenotypes and how sometimes these mutations affect only specific tissues or cell types 461 
[16, 111]. The elucidation of the basis of these ribosome-related diseases requires a better 462 
knowledge of the ribosome, especially its biogenesis, which seems to be altered in a 463 
relatively high number of ribosomopathies. And in these studies, Saccharomyces cerevisiae 464 
has been an important model organism [112-113]. 465 
TABLE 1.- List of gene defects associated to ribosomopathies and their related diseases 466 
(Adapted from 
114
). 467 
 468 
GENE DEFECT IMPAIRED FUNCTION DISEASE CLINICAL FEATURES TREATMENT REFERENCES 
RPS19, RPS26, 
RPL5, RPL11 
and other RPs 
Different steps of pre-rRNA 
processing 
Diamond Blackfan 
anemia (DBA) 
Anemia, bone marrow failure, growth 
retardation, congenital abnormalities 
(craniofacial, thumb), cardiac defects, 
cancer predisposition. 
Corticosteroids, blood 
transfusions, 
hematopoietic stem 
cell transplantation 
[115-121] 
RPS14 18S pre-rRNA processing 5q-syndrome 
Severe macrocytic anemia, cancer 
predisposition 
Lenalidomide [122-123] 
SBDS 
Maturation and export of the 
60S ribosomal subunit 
Shwachman-
Diamond syndrome 
(SDS) 
Exocrine pancreas insufficiency, 
hematologic defects, skeletal 
abnormalities, cancer predisposition 
Pancreatic enzyme 
supplementation, 
hematopoietic stem 
cell transplantation 
[124-126] 
DKC1 
Telomerase deficiency, disease 
aggravated by box H/ACA 
snoRNP pseudouridylation 
defects, involved in pre-rRNA 
modification. 
X-linked 
dyskeratosis 
congenita (DC) 
Mucocutaneous abnormalities, 
pulmonary fibrosis, bone marrow 
failure, cancer predisposition 
Oxymetolone, 
Hematopoietic stem 
cell transplantation 
[127-129] 
RMRP 
Maturation of 5.8S rRNA of 
60S ribosomal subunit; 
degradation of cell-cycle 
regulated RNAs; mitochondrial 
DNA replication 
Cartilage-hair 
hypoplasia (CHH) 
Short stature, hair hypoplasia, bone 
deformities, cancer predisposition 
Symptomatic [130-131] 
TCOF1 
rDNA transcription and 
methylation of 18S rRNA 
Treacher-Collins 
syndrome (TCS) 
Craniofacial abnormalities Symptomatic [132-134] 
EMG1 
Maturation of 40S ribosomal 
subunit 
Bowen-Conradi 
syndrome 
Severe growth retardation None [135-137] 
hUTP4/Cirhin 
Maturation of the 18S pre-
rRNA 
North American 
Indian childhood 
cirrhosis 
Biliary cirrhosis, lethal by 
adolescence without liver transplant 
Liver transplantation [138-140] 
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Ribosome biogenesis is a complex cellular process where the large and small ribosomal 469 
subunits are assembled. In eukaryotes, this process starts in the nucleolus. Then, both 470 
subunits undergo maturation through the nucleoplasm and the cytoplasm (Fig. 6). More 471 
than 300 factors, including proteins and RNAs are involved in the production of a mature 472 
ribosome in the yeast S. cerevisiae. In humans, this number is even higher, in accordance to 473 
the bigger size and complexity of human ribosomes [110, 141]. This complex maturation 474 
process begins with transcription of 5S and 35S pre-rRNA in the nucleolus, acquiring post-475 
transcriptional modifications and associating with ribosomal proteins as well as other trans-476 
acting factors to form the 90S particle. This particle is then cleaved, releasing pre-40S and 477 
pre-60S particles that undergo independent maturation pathways. Pre-40S are rapidly 478 
exported to the cytoplasm with relatively few compositional changes. Maturation of the 479 
pre-60S particle is much more complex and involves several changes of composition in the 480 
nucleoplasm. Once in the cytoplasm, major events include the release of factors from the 481 
exit tunnel, the assembly of the stalk structure (ribosomal proteins P0, P1 and P2), and the 482 
release of the anti-association factor Tif6 (eIF6 in humans), by Sdo1 and the GTPase Efl1 483 
[112-113, 142-145]. Mutations in the human orthologue of Sdo1, SBDS, are responsible for 484 
most of the cases of the Shwachman-Diamond syndrome [109, 146]. 485 
Figure 6.- Ribosome biogenesis and pre-rRNA processing pathways in yeast. 486 
Schematic representation of ribosome maturation, that starts with RNA Pol I and III 487 
transcribing 35S and 5S pre-rRNAs, respectively. These rRNAs associate to ribosomal 488 
proteins and other factors building the 90S particle. After cleavage of 35S pre-rRNA, the 489 
90S particle separates into a pre-60S (blue) and a pre-40S subunit (green), which undergo 490 
independent maturation. Maturation driven by numerous assembly factors occurs while 491 
these particles travel through the nucleoplasm. Once in the cytoplasm final maturation 492 
yields translational competent ribosomal particles. Ribotoxins target mature 60S subunits, 493 
but pre-60S subunits and the whole ribosome biogenesis pathway might also be affected by 494 
their toxicity. 495 
 496 
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 497 
Thanks to powerful techniques like the tandem affinity purification, combined with mass 498 
spectrometry, the knowledge of ribosome biogenesis has significantly increased over the 499 
past 20 years. However, many questions regarding this complex event are still unanswered. 500 
Fungal ribotoxins may shed some light in this sense. From their point of view, it would be 501 
interesting to see whether these toxins can access the nucleus, and if they do, whether the 502 
SRL of pre-60S particles can be cleaved. From the ribosome biogenesis side, they might be 503 
appropriate tools to explore the maturation pathway of pre-60S particles, especially in the 504 
cytoplasm, since their target, the SRL, is localized in a region essential during this process. 505 
In fact, Efl1 binds to the SRL to release the anti-association factor eIF6 [147]. Moreover, 506 
understanding how ribotoxins affect mature and immature ribosomes may give some 507 
information about pre-rRNA processing and folding, and the function and localization of 508 
some trans-acting factors. Eventually, these studies may contribute to a better 509 
understanding of pathologies like the already mentioned Shwachman-Diamond syndrome 510 
and other ribosomopathies. 511 
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5. CONCLUDING REMARKS. 512 
 513 
Over the past decades, the structure and function of fungal ribotoxins have been extensively 514 
studied. Today, the accumulated knowledge of this family of toxins has allowed their 515 
successful use in some downstream applications, like the design of new specific 516 
immunotoxins against colon cancer and the establishment of mouse models for the study of 517 
Aspergillosis. However, the range of potential applications does not end here. The 518 
discovery of HtA supports the idea that, in nature, ribotoxins have a major role as defensive 519 
toxins with insecticidal activity. Their high efficiency against insect cells and larvae make 520 
them good candidates for the design and development of new biopesticides. Furthermore, 521 
ribotoxins could be also used in the field of ribosome biogenesis, contributing to a better 522 
understanding of ribosomopathies.  523 
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